In adults with type 2 diabetes and obesity, a drug called bimagrumab reduces waist size by 9.0 centimeters more than a placebo after 48 weeks, and this reduction is specifically due to loss of visceral fat in the abdomen.
See the scientific wording
In adults with type 2 diabetes and obesity, administration of bimagrumab for 48 weeks results in a 9.0 cm greater reduction in waist circumference compared to placebo, indicating a preferential reduction in abdominal visceral fat.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
Randomized Controlled TrialHuman2021
The study found that people with type 2 diabetes and obesity who took bimagrumab lost 9 cm off their waistline — way more than those who took a placebo — which means it likely targeted the dangerous belly fat that raises diabetes and heart disease risk.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug blocks a signal that normally limits muscle growth, causing muscles to get bigger. Bigger muscles burn more energy, and the body starts breaking down fat stored around the organs in the belly. This fat loss is especially strong in the abdomen, making the waist smaller.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with type 2 diabetes and obesity, a drug called bimagrumab reduces waist size by 9.0 centimeters more than a placebo after 48 weeks, and this reduction is specifically due to loss of visceral fat in the abdomen.
Mechanism
1 studyA drug blocks a signal that stops muscles from growing, so muscles get bigger and burn more energy. At the same time, the drug changes how fat is stored, causing the body to break down the dangerous fat around the organs in the belly. This makes the waist smaller.
A drug blocks a signal that normally limits muscle growth, causing muscles to get bigger. Bigger muscles burn more energy, and the body starts breaking down fat stored around the organs in the belly. This fat loss is especially strong in the abdomen, making the waist smaller.
Bimagrumab binds to activin type II receptors on skeletal muscle and adipose tissue cells, preventing ligands such as myostatin and activin from activating these receptors
Blockade of activin type II receptor signaling removes inhibition of the Akt/mTOR pathway in skeletal muscle, leading to increased protein synthesis and skeletal muscle hypertrophy
Increased skeletal muscle mass elevates whole-body energy expenditure and basal metabolic rate
Activin type II receptor inhibition in adipose tissue promotes remodeling of white adipose tissue and enhances thermogenic activity, reducing lipid storage in visceral depots
Reduction in visceral adipose tissue and ectopic fat in the liver decreases systemic inflammation and improves insulin sensitivity
Preferential loss of abdominal visceral fat results in a measurable reduction in waist circumference
Evidence from Studies
Supporting (1)
Community contributions welcome
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
The study found that people with type 2 diabetes and obesity who took bimagrumab lost 9 cm off their waistline — way more than those who took a placebo — which means it likely targeted the dangerous belly fat that raises diabetes and heart disease risk.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Bimagrumab Trials on Waist Circumference and Visceral Fat in Type 2 Diabetes and Obesity
Population: Adults with type 2 diabetes and obesity; Intervention: Bimagrumab; Comparator: Placebo; Outcome: Change in waist circumference and visceral fat mass by imaging; Duration: 48 weeks; Inclusion: All published randomized controlled trials with at least 12 weeks of follow-up.
Double-Blind, Placebo-Controlled Trial of Bimagrumab for Waist Circumference and Visceral Fat Reduction in Type 2 Diabetes and Obesity Over 48 Weeks
Population: Adults with type 2 diabetes and obesity (n≥200); Intervention: Bimagrumab at standard clinical dose; Comparator: Placebo; Outcome: Primary: change in waist circumference by dual-energy X-ray absorptiometry; Secondary: visceral fat area by CT scan; Duration: 48 weeks; Design: Randomized, double-blind, parallel-group.
Prospective Cohort Study of Bimagrumab Use and Changes in Waist Circumference and Visceral Fat in Real-World Type 2 Diabetes and Obesity Patients Over 48 Weeks
Population: Adults with type 2 diabetes and obesity receiving bimagrumab in clinical practice; Comparator: Matched controls not receiving bimagrumab; Outcome: Change in waist circumference and visceral fat over 48 weeks; Duration: 48 weeks; Design: Prospective, observational, with baseline and follow-up imaging.
In Vitro Analysis of Bimagrumab's Effect on Human Adipocyte Lipolysis and Visceral Fat Cell Metabolism
Population: Human visceral adipocytes derived from subcutaneous and omental fat biopsies; Intervention: Exposure to bimagrumab at pharmacologically relevant concentrations; Comparator: Vehicle control; Outcome: Lipolysis rate, gene expression of fat metabolism markers, lipid droplet size; Duration: 72 hours.
Animal Model Study of Bimagrumab on Abdominal Fat Mass in Diet-Induced Obese Mice with Insulin Resistance
Population: C57BL/6 mice with diet-induced obesity and insulin resistance; Intervention: Bimagrumab administered via injection; Comparator: Saline vehicle; Outcome: Visceral fat mass, glucose tolerance, adipocyte size; Duration: 12 weeks.